MX2023014547A - Proceso para la preparacion de inhibidores de familia de receptores tipo nod con dominio pirina 3 (nlrp3). - Google Patents
Proceso para la preparacion de inhibidores de familia de receptores tipo nod con dominio pirina 3 (nlrp3).Info
- Publication number
- MX2023014547A MX2023014547A MX2023014547A MX2023014547A MX2023014547A MX 2023014547 A MX2023014547 A MX 2023014547A MX 2023014547 A MX2023014547 A MX 2023014547A MX 2023014547 A MX2023014547 A MX 2023014547A MX 2023014547 A MX2023014547 A MX 2023014547A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- indacen
- hexahydro
- sulfonamide
- piperidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/98—Nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202141028180 | 2021-06-23 | ||
| PCT/EP2022/067126 WO2022268935A2 (en) | 2021-06-23 | 2022-06-23 | Novel process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014547A true MX2023014547A (es) | 2024-04-29 |
Family
ID=82458485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014547A MX2023014547A (es) | 2021-06-23 | 2022-06-23 | Proceso para la preparacion de inhibidores de familia de receptores tipo nod con dominio pirina 3 (nlrp3). |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240150291A1 (enExample) |
| EP (1) | EP4359385A2 (enExample) |
| JP (1) | JP2024524215A (enExample) |
| KR (1) | KR20240024842A (enExample) |
| CN (1) | CN118019727A (enExample) |
| AR (1) | AR126215A1 (enExample) |
| AU (1) | AU2022300325A1 (enExample) |
| CA (1) | CA3219597A1 (enExample) |
| IL (1) | IL308071A (enExample) |
| MX (1) | MX2023014547A (enExample) |
| TW (1) | TW202317514A (enExample) |
| WO (1) | WO2022268935A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023220628A1 (en) * | 2022-02-15 | 2024-05-23 | F. Hoffmann-La Roche Ag | Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives |
| WO2024133610A1 (en) * | 2022-12-23 | 2024-06-27 | F. Hoffmann-La Roche Ag | Proccesses for the preparation of an nlrp3 inhibitor |
| WO2025036914A1 (en) | 2023-08-16 | 2025-02-20 | F. Hoffmann-La Roche Ag | Process for the preparation of preparing 1-ethyl-n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)piperidine-4-sulfonamide |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA917435B (en) * | 1990-09-26 | 1992-05-27 | Takeda Chemical Industries Ltd | Herbicides |
| CA2059450A1 (en) * | 1991-01-24 | 1992-07-25 | Nobuyuki Sakashita | Subsituted pyridinesulfonamide compound or its salt, process for preparing the same, and herbicide containing the same |
| JP2001518069A (ja) * | 1997-05-02 | 2001-10-09 | ドクター・レディーズ・リサーチ・ファウンデーション | 低脂質性、抗高血圧性特性を有する新規な抗糖尿病化合物、それらの製造方法及びそれらを含有する薬学的組成物 |
| ATE342266T1 (de) * | 2000-11-16 | 2006-11-15 | Sankyo Co | 1-methylcarbapenemderivate |
| US7199147B2 (en) * | 2001-06-12 | 2007-04-03 | Dainippon Sumitomo Pharma Co., Ltd. | Rho kinase inhibitors |
| MXPA04010172A (es) * | 2002-04-18 | 2005-02-03 | Schering Corp | 1-(4-piperidinil)benzimidazolonas como antagonistas de histamina h3). |
| US7759387B2 (en) * | 2003-10-08 | 2010-07-20 | Piramal Life Sciences Limited | Fibrinogen receptor antagonists and their use |
| DOP2006000009A (es) * | 2005-01-13 | 2006-08-15 | Arena Pharm Inc | Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina |
| US8614215B2 (en) * | 2007-02-22 | 2013-12-24 | Merck Serono Sa | Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) |
| US20120196889A1 (en) * | 2009-02-25 | 2012-08-02 | H. Lundbeck A/S | Catecholamine derivatives and prodrugs thereof |
| JP5898962B2 (ja) * | 2012-01-11 | 2016-04-06 | 東京応化工業株式会社 | レジスト組成物及びレジストパターン形成方法 |
| EP3383853B1 (en) * | 2015-12-01 | 2020-11-04 | Merck Sharp & Dohme Corp. | Homobispiperidinyl derivatives as liver x receptor (lxr) beta agonists for treating e.g. alzheimer's disease |
| KR102669722B1 (ko) * | 2017-07-07 | 2024-05-29 | 인플라좀 리미티드 | 신규한 설폰아마이드 카복스아마이드 화합물 |
| GB201712282D0 (en) * | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
| SG11202001164SA (en) * | 2017-08-15 | 2020-03-30 | Inflazome Ltd | Novel sulfonamide carboxamide compounds |
| KR20210018199A (ko) * | 2018-03-26 | 2021-02-17 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스의 분해를 위한 세레블론 결합제 |
| MA52489A (fr) * | 2018-05-04 | 2021-03-10 | Inflazome Ltd | Nouveaux composés |
| CA3113573A1 (en) * | 2018-09-21 | 2020-03-26 | Novartis Ag | Isoxazole carboxamide compounds and uses thereof |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| GB201819083D0 (en) * | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| WO2020157069A1 (en) * | 2019-01-28 | 2020-08-06 | NodThera Limited | Amino heterocyclic compounds and uses thereof |
| CN111393415B (zh) * | 2020-04-30 | 2020-11-20 | 苏州信诺维医药科技有限公司 | 一种杂芳腈类化合物及其应用 |
-
2022
- 2022-06-23 MX MX2023014547A patent/MX2023014547A/es unknown
- 2022-06-23 TW TW111123528A patent/TW202317514A/zh unknown
- 2022-06-23 EP EP22738569.7A patent/EP4359385A2/en active Pending
- 2022-06-23 JP JP2023578919A patent/JP2024524215A/ja active Pending
- 2022-06-23 KR KR1020237044161A patent/KR20240024842A/ko active Pending
- 2022-06-23 WO PCT/EP2022/067126 patent/WO2022268935A2/en not_active Ceased
- 2022-06-23 AR ARP220101651A patent/AR126215A1/es unknown
- 2022-06-23 CA CA3219597A patent/CA3219597A1/en active Pending
- 2022-06-23 AU AU2022300325A patent/AU2022300325A1/en active Pending
- 2022-06-23 CN CN202280045202.0A patent/CN118019727A/zh active Pending
- 2022-06-23 IL IL308071A patent/IL308071A/en unknown
-
2023
- 2023-12-19 US US18/545,711 patent/US20240150291A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR126215A1 (es) | 2023-09-27 |
| US20240150291A1 (en) | 2024-05-09 |
| CN118019727A (zh) | 2024-05-10 |
| TW202317514A (zh) | 2023-05-01 |
| AU2022300325A8 (en) | 2023-11-16 |
| AU2022300325A1 (en) | 2023-11-02 |
| JP2024524215A (ja) | 2024-07-05 |
| WO2022268935A3 (en) | 2023-02-02 |
| KR20240024842A (ko) | 2024-02-26 |
| IL308071A (en) | 2023-12-01 |
| EP4359385A2 (en) | 2024-05-01 |
| CA3219597A1 (en) | 2022-12-29 |
| WO2022268935A2 (en) | 2022-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021004431A (es) | Procesos novedosos. | |
| PH12021550166A1 (en) | Nlrp3 inflammasome inhibitors | |
| JOP20210307A1 (ar) | مثبطات جسيم التهابي nlrp3 | |
| WO2024120378A3 (en) | Triazole compounds, preparation methods and medicinal uses thereof | |
| CR20230261A (es) | Cocristal de un inhibidor de cdk | |
| GEAP202315746A (en) | Protein tyrosine phosphatase inhibitors | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| WO2022268935A3 (en) | Process for the preparation of nlrp3 inhibitors | |
| ZA202403388B (en) | Small molecules for treatement of cancer | |
| MX2020011196A (es) | Una sal sodica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamo il)-1-isopropil-1h-pirazol-3-sulfonamida. | |
| MX2023003627A (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer. | |
| WO2020247298A3 (en) | 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
| CA3200722A1 (en) | Heteroaryl-acetylenes, pharmaceutical compositions thereof, and their therapeutic applications | |
| MX2022004878A (es) | Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos. | |
| PH12021551232A1 (en) | Haloallylamine compounds and application thereof | |
| MX2025001865A (es) | Compuestos de piridinona sustituida como inhibidores de cbl-b | |
| MX2024014315A (es) | Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas | |
| MX2025014163A (es) | Azinas condensadas como inhibidores de tyk2 y usos de las mismas | |
| MX2025012370A (es) | Compuesto de amida, composicion farmaceutica que comprende el compuesto y uso de esta | |
| PH12021550258A1 (en) | Cdk8/19 inhibitors | |
| MX2023015377A (es) | Sal de potasio cristalina de 1-etil-n-((1,2,3,5,6,7-hexahidro-s-in dacen-4-il)carbamoil)piperidin-4-sulfonamida. | |
| CA3242600A1 (en) | Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives | |
| MX2023014784A (es) | Preparacion de derivados de compuestos 1,2-diaminoheterociclicos sustituidos y su uso como agentes farmaceuticos. | |
| WO2022204344A3 (en) | Enamine n-oxides: synthesis and application to hypoxia-responsive prodrugs and imaging agents | |
| EP4248960A3 (en) | Novel triterpene derivatives as hiv inhibitors |